ALPCO’s automated turbidimetric solution for calprotectin testing offers enhanced efficiency without compromising clinical sensitivity or specificity. Clinicians can prioritize endoscopic evaluation for the patients that need it most and quickly put IBS patients on the right treatment path. 

ALPCO offers targeted GI solutions suitable for all types of labs. Our offerings range from plate-based to clinical chemistry analyzer-based and automated flash chemiluminescence solutions, all designed to accommodate your lab’s expanding testing needs and capabilities.

In an effort to improve patient care, an increasing number of gastroenterologists are using fecal calprotectin levels as a first step in the diagnosis of IBD versus IBS. ALPCO tests enable clinicians to accurately assess patients via calprotectin and quickly start patients on the right treatment path.

Food sensitivity or food intolerance involves a non-allergic response to a food or food additive. In a recent on-line survey conducted in the U.S., 24% of adults aged 18 to 79 reported a food intolerance. While a food allergy is typically mediated by IgE antibodies, adverse reactions to food observed in patients with functional GI  disorders, such as IBS, may be due to a delayed immunological response involving Immunoglobulin G (IgG) antibodies. Problem foods and food additives are believed to activate mast cells through the binding of IgG antibodies. Increased intestinal mast cell activation has been demonstrated in cases of IBD and IBS.

Cases of food and environmental allergies have been increasing over the last decade. While conservative estimates suggest IgE-mediated allergy affects 6-8% of children and 2-3% of adults, some estimates are as high as 30%.3, 2 Symptoms can range from mild to severe and include itching, hives, vomiting, diarrhea, and constricted breathing. A severe allergic reaction, termed anaphylaxis, ...

800 million people worldwide struggle with obesity, a disease poised to cost over $1 trillion in medical consequences by 2025. Over 40% of the US population is impacted, according to the Centers for Disease Control. Obesity is a major risk factor in the development of illnesses that lead to diabetes, such as insulin resistance, hypertension, and other metabolic disorders. Long-term disrupti...

 60 to 70 million Americans are affected by gastrointestinal (GI) diseases and disorders each year. The estimated annual U.S. cost associated with GI disorders is over 140 billion dollars. Gl diseases and disorders can have a significant impact on quality of life, often contributing to anxiety and depression.2 The ongoing challenge relates to overlapping symptoms and the compl...

Digestive Diseases Affect More than 70 Million Americans Each Year. The estimated annual cost of GI disorders is $135 billion, with patients reporting a higher incidence of depression and absenteeism. Comparatively, approximately 34 million Americans have diabetes.

Cases of food and environmental allergies have been increasing over the last decade. While conservative estimates suggest IgE-mediated allergy affects 6-8% of children and 2-3% of adults, some estimates are as high as 30%.3, 2 Symptoms can range from mild to severe and include itching, hives, vomiting, diarrhea, and constricted breathing. A severe allergic reaction, termed anaphylaxis, ...

800 million people worldwide struggle with obesity, a disease which will cost over $1 trillion in medical consequences by 2025.  The CDC reports that severe obesity leads to life-altering and often life-threatening conditions like heart disease, stroke, type 2 diabetes, and certain cancers. What is the “Incretin Effect”? To help understand the mechanisms behind obesity and to develop trea...